Trial Site Detail

 

Drug:
Rogaratinib
Trial:
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Conditions: Sarcoma
Trial Status:
Completed

 

National Cancer Institute

Building 10, Room 4-3760     10 Center Drive
Bethesda , MD 20892
USA

 

Principal Investigator:
 A. P. Chan
Contact:
 Site Public Contact 800-411-1222
Activation Status of this Site:
 Active
Notes about this Site:
National Cancer Institute Website:
 http://www.cc.nih.gov/index.html

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.